Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.
de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S. de Kruijff IE, et al. Among authors: meijer van gelder me. Cancers (Basel). 2018 May 5;10(5):134. doi: 10.3390/cancers10050134. Cancers (Basel). 2018. PMID: 29734758 Free PMC article.
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.
Sieuwerts AM, Lyng MB, Meijer-van Gelder ME, de Weerd V, Sweep FC, Foekens JA, Span PN, Martens JW, Ditzel HJ. Sieuwerts AM, et al. Among authors: meijer van gelder me. Mol Oncol. 2014 Dec;8(8):1679-89. doi: 10.1016/j.molonc.2014.07.003. Epub 2014 Jul 10. Mol Oncol. 2014. PMID: 25081647 Free PMC article.
GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, Smid M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW. Liu J, et al. Among authors: meijer van gelder me. Cancer Lett. 2016 Jun 28;376(1):104-9. doi: 10.1016/j.canlet.2016.03.038. Epub 2016 Mar 24. Cancer Lett. 2016. PMID: 27018307 Free article.
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Jansen MP, Martens JW, Helmijr JC, Beaufort CM, van Marion R, Krol NM, Monkhorst K, Trapman-Jansen AM, Meijer-van Gelder ME, Weerts MJ, Ramirez-Ardila DE, Dubbink HJ, Foekens JA, Sleijfer S, Berns EM. Jansen MP, et al. Among authors: meijer van gelder me. Oncotarget. 2016 Jul 12;7(28):43412-43418. doi: 10.18632/oncotarget.9727. Oncotarget. 2016. PMID: 27270325 Free PMC article.
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM. van Schaik RH, et al. Pharmacogenomics. 2011 Aug;12(8):1137-46. doi: 10.2217/pgs.11.54. Epub 2011 Aug 10. Pharmacogenomics. 2011. PMID: 21830868
54 results